We are live on ! Find out more
PA

PharVision Advisers Portfolio holdings

AUM $9.86M
1-Year Est. Return 9.93%
This Fund
S&P 500
This Quarter Est. Return
-7.09%
1 Year Est. Return
+9.93%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$9.86M
AUM Growth
-$188M
Cap. Flow
-$186M
Cap. Flow %
-1,882.29%
Top 10 Hldgs %
17.98%
Holding
708
New
41
Increased
5
Reduced
51
Closed
611

Top Buys

Rank Stock Value
1
ACVA icon
ACV Auctions
ACVA
+$194K
2
RPD icon
Rapid7
RPD
+$183K
3
EFC
Ellington Financial
EFC
+$181K
4
SAN icon
Banco Santander
SAN
+$159K
5
OSCR icon
Oscar Health
OSCR
+$155K

Top Sells

Rank Stock Value
1
EXLS icon
EXL Service
EXLS
+$830K
2
DK icon
Delek US
DK
+$724K
3
AVGO icon
Broadcom
AVGO
+$669K
4
ITRI icon
Itron
ITRI
+$666K
5
EAT icon
Brinker International
EAT
+$649K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 17.83%
2 Technology 15.87%
3 Healthcare 10.98%
4 Industrials 10.86%
5 Real Estate 9.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HPQ icon
1
HP
HPQ
$22.1B
$233K 2.36%
12,118
-6,906
-36% -$134K
MLCO icon
2
Melco Resorts & Entertainment
MLCO
$2.13B
$199K 2.02%
35,072
-27,604
-44% -$167K
FSM icon
3
Fortuna Silver Mines
FSM
$2.43B
$183K 1.85%
18,393
-1,502
-8% -$16.3K
HLF icon
4
Herbalife
HLF
$1.27B
$176K 1.78%
11,930
-37,985
-76% -$621K
SWBI icon
5
Smith & Wesson
SWBI
$671M
$176K 1.78%
12,248
-15,827
-56% -$192K
EFC
6
Ellington Financial
EFC
$1.68B
$169K 1.72%
+14,267
New +$181K
ATEC icon
7
Alphatec Holdings
ATEC
$1.27B
$166K 1.68%
15,222
+3,043
+25% +$44.3K
DCH
8
Dauch Corp
DCH
$1.26B
$163K 1.65%
27,417
-48,377
-64% -$336K
SB icon
9
Safe Bulkers
SB
$729M
$158K 1.61%
+25,033
New +$146K
SAN icon
10
Banco Santander
SAN
$191B
$150K 1.52%
+13,320
New +$159K
F icon
11
Ford
F
$55.7B
$150K 1.52%
12,996
-2,984
-19% -$39.3K
QUAD icon
12
Quad
QUAD
$444M
$145K 1.47%
+21,901
New +$141K
OIS icon
13
Oil States International
OIS
$497M
$142K 1.44%
+12,212
New +$126K
ALTG icon
14
Alta Equipment Group
ALTG
$201M
$141K 1.43%
26,305
-64,108
-71% -$407K
AGNC icon
15
AGNC Investment
AGNC
$12.5B
$140K 1.43%
+14,007
New +$155K
EMBC icon
16
Embecta
EMBC
$204M
$140K 1.42%
15,877
+4,642
+41% +$48.4K
CNH
17
CNH Industrial
CNH
$12.8B
$139K 1.42%
+12,680
New +$143K
FVRR icon
18
Fiverr
FVRR
$413M
$136K 1.39%
13,622
-22,004
-62% -$302K
RIG icon
19
Transocean
RIG
$5.56B
$135K 1.37%
+20,339
New +$115K
NEXT icon
20
NextDecade
NEXT
$2.04B
$134K 1.36%
+17,550
New +$99.8K
ZGN icon
21
Zegna
ZGN
$3.74B
$132K 1.34%
+12,690
New +$131K
PGY icon
22
Pagaya Technologies
PGY
$1.42B
$131K 1.33%
11,225
-13,392
-54% -$212K
AVAH icon
23
Aveanna Healthcare
AVAH
$2.11B
$129K 1.31%
20,092
-21,059
-51% -$163K
MITT
24
TPG Mortgage Investment Trust
MITT
$239M
$128K 1.3%
+17,565
New +$145K
ORC
25
Orchid Island Capital
ORC
$1.34B
$128K 1.3%
18,180
-31,357
-63% -$237K

Similar funds

PharVision Advisers's Q1 2026 Portfolio in Review

As of Q1 2026, PharVision Advisers held 708 positions worth $9.86M, down 95% from $198M the previous quarter. Its ten largest holdings account for 18% of the portfolio.

PharVision Advisers withdrew a net $186M in Q1 2026, closing 611 positions and reducing 51 holdings. Its most notable exit was EXL Service, an estimated $830K position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.

Against the trend, PharVision Advisers opened a new position in ACV Auctions worth $125K.

  • PharVision Advisers's largest Q1 2026 buy was ACV Auctions: 29,579 shares worth $125K.
  • PharVision Advisers added most to Embecta in Q1 2026, an estimated $48.4K increase.
  • PharVision Advisers's biggest Q1 2026 reduction was Herbalife, cutting an estimated $621K.
  • PharVision Advisers fully exited EXL Service in Q1 2026, selling an estimated $830K.
  • PharVision Advisers's ten largest holdings make up 18% of its $9.86M portfolio in Q1 2026.
  • PharVision Advisers opened 41 new positions and closed 611 in Q1 2026.
  • PharVision Advisers's portfolio value fell 95% quarter-over-quarter to $9.86M.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.